136 related articles for article (PubMed ID: 38086530)
21. Complex Characterization of Germline Large Genomic Rearrangements of the
Bozsik A; Pócza T; Papp J; Vaszkó T; Butz H; Patócs A; Oláh E
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32629901
[TBL] [Abstract][Full Text] [Related]
22. Emerging cancer risks in BRCA2 pathogenic germline variant carriers.
Benusiglio PR; Dardenne A; Fallet V; Cadranel J
Eur J Hum Genet; 2023 Dec; 31(12):1355-1356. PubMed ID: 37758835
[No Abstract] [Full Text] [Related]
23. Prevalence of germline pathogenic
Morgan RD; Burghel GJ; Flaum N; Bulman M; Clamp AR; Hasan J; Mitchell CL; Schlecht H; Woodward ER; Lallo FI; Crosbie EJ; Edmondson RJ; Wallace AJ; Jayson GC; Evans DGR
J Med Genet; 2019 May; 56(5):301-307. PubMed ID: 30683677
[TBL] [Abstract][Full Text] [Related]
24. Germline and tumor BRCA1/2 pathogenic variants in Chinese triple-negative breast carcinomas.
Ji G; Bao L; Yao Q; Zhang J; Zhu X; Bai Q; Shao Z; Yang W; Zhou X
J Cancer Res Clin Oncol; 2021 Oct; 147(10):2935-2944. PubMed ID: 34254208
[TBL] [Abstract][Full Text] [Related]
25. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
[TBL] [Abstract][Full Text] [Related]
26. Clinical application of artificial neural network (ANN) modeling to predict BRCA1/2 germline deleterious variants in Chinese bilateral primary breast cancer patients.
Li Y; Chen L; Lv J; Chen X; Zeng B; Chen M; Guo W; Lin Y; Yu L; Hou J; Li J; Zhou P; Zhang W; Li S; Jin X; Cai W; Zhang K; Huang Y; Wang C; Fu F
BMC Cancer; 2022 Nov; 22(1):1125. PubMed ID: 36324133
[TBL] [Abstract][Full Text] [Related]
27. Targeted capture-based NGS is superior to multiplex PCR-based NGS for hereditary BRCA1 and BRCA2 gene analysis in FFPE tumor samples.
Zakrzewski F; Gieldon L; Rump A; Seifert M; Grützmann K; Krüger A; Loos S; Zeugner S; Hackmann K; Porrmann J; Wagner J; Kast K; Wimberger P; Baretton G; Schröck E; Aust D; Klink B
BMC Cancer; 2019 Apr; 19(1):396. PubMed ID: 31029168
[TBL] [Abstract][Full Text] [Related]
28. Frequency of germline BRCA1/2 mutations and association with clinicopathological characteristics in Turkish women with epithelial ovarian cancer.
Sunar V; Korkmaz V; Topcu V; Cavdarli B; Arik Z; Ozdal B; Ustun YE
Asia Pac J Clin Oncol; 2022 Feb; 18(1):84-92. PubMed ID: 33629534
[TBL] [Abstract][Full Text] [Related]
29. Germline landscape of BRCAs by 7-site collaborations as a BRCA consortium in Turkey.
Bisgin A; Sag SO; Dogan ME; Yildirim MS; Gumus AA; Akkus N; Balasar O; Durmaz CD; Eroz R; Altiner S; Alemdar A; Aliyeva L; Boga I; Cam FS; Dogan B; Esbah O; Hanta A; Mujde C; Ornek C; Ozer S; Rencuzogullari C; Sonmezler O; Bozdogan ST; Dundar M; Temel SG
Breast; 2022 Oct; 65():15-22. PubMed ID: 35753294
[TBL] [Abstract][Full Text] [Related]
30. Predicting the likelihood of a
Morgan RD; Burghel GJ; Flaum N; Bulman M; Smith P; Clamp AR; Hasan J; Mitchell C; Salih Z; Woodward ER; Lalloo F; Shaw J; Desai S; Crosbie EJ; Edmondson RJ; Schlecht H; Wallace AJ; Jayson GC; Evans DGR
J Clin Pathol; 2023 Oct; 76(10):684-689. PubMed ID: 35738887
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: a portrait of early-onset breast cancer in Brazil.
Carraro DM; Koike Folgueira MA; Garcia Lisboa BC; Ribeiro Olivieri EH; Vitorino Krepischi AC; de Carvalho AF; de Carvalho Mota LD; Puga RD; do Socorro Maciel M; Michelli RA; de Lyra EC; Grosso SH; Soares FA; Achatz MI; Brentani H; Moreira-Filho CA; Brentani MM
PLoS One; 2013; 8(3):e57581. PubMed ID: 23469205
[TBL] [Abstract][Full Text] [Related]
32. BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: A cohort study.
Kitson SJ; Bafligil C; Ryan NAJ; Lalloo F; Woodward ER; Clayton RD; Edmondson RJ; Bolton J; Crosbie EJ; Evans DG
Eur J Cancer; 2020 Sep; 136():169-175. PubMed ID: 32698099
[TBL] [Abstract][Full Text] [Related]
33. The RAD52 S346X variant reduces risk of developing breast cancer in carriers of pathogenic germline BRCA2 mutations.
Adamson AW; Ding YC; Mendez-Dorantes C; Bailis AM; Stark JM; Neuhausen SL
Mol Oncol; 2020 Jun; 14(6):1124-1133. PubMed ID: 32175645
[TBL] [Abstract][Full Text] [Related]
34. BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects.
Apostolou P; Fostira F; Kouroussis C; Kalfakakou D; Delimitsou A; Agelaki S; Androulakis N; Christodoulou C; Kalbakis K; Kalykaki A; Sanidas E; Papadimitriou C; Vamvakas L; Georgoulias V; Mavroudis D; Yannoukakos D; Konstantopoulou I; Saloustros E
Int J Cancer; 2020 Sep; 147(5):1334-1342. PubMed ID: 32022259
[TBL] [Abstract][Full Text] [Related]
35. BRCA1 and BRCA2 germline mutation analysis from a cohort of 1267 patients at high risk for breast cancer in Brazil.
Mazzonetto P; Milanezi F; D'Andrea M; Martins S; Monfredini PM; Dos Santos Silva J; Perrone E; Villela D; Schnabel B; Nakano V; Palmero EI; Braggio E; Cavalcanti TL; Guida G; Migliavacca MP; Scapulatempo-Neto C; Zalcberg I
Breast Cancer Res Treat; 2023 May; 199(1):127-136. PubMed ID: 36881271
[TBL] [Abstract][Full Text] [Related]
36. MUTATIONS OF GENES BRCA1 AND BRCA2 IN WOMEN WITH OVARIAN CANCER EXPOSED TO FACTORS OF CHORNOBYL NUCLEAR ACCIDENT.
Rybchenko LA; Poluben LO; Bychkova GM; Stephanovych GV; Klymenko SV
Probl Radiac Med Radiobiol; 2019 Dec; 24():455-464. PubMed ID: 31841487
[TBL] [Abstract][Full Text] [Related]
37. Pathogenic Germline Variants in BRCA1/2 and p53 Identified by Real-world Comprehensive Cancer Genome Profiling Tests in Asian Patients.
Satake T; Kondo S; Tanabe N; Mizuno T; Katsuya Y; Sato J; Koyama T; Yoshida T; Hirata M; Yamamoto N
Cancer Res Commun; 2023 Nov; 3(11):2302-2311. PubMed ID: 37916805
[TBL] [Abstract][Full Text] [Related]
38. Germline Pathogenic Variants in
Lieberman S; Goldvaser H; Levy-Lahad E
J Clin Oncol; 2022 May; 40(14):1590-1594. PubMed ID: 35286153
[No Abstract] [Full Text] [Related]
39. Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia.
Ben Ayed-Guerfali D; Ben Kridis-Rejab W; Ammous-Boukhris N; Ayadi W; Charfi S; Khanfir A; Sellami-Boudawara T; Frikha M; Daoud J; Mokdad-Gargouri R
J Transl Med; 2021 Mar; 19(1):108. PubMed ID: 33726785
[TBL] [Abstract][Full Text] [Related]
40. Breast cancer in East Africa: Prevalence and spectrum of germline SNV/indel and CNVs in BRCA1 and BRCA2 genes among breast cancer patients in Tanzania.
Rweyemamu LP; Gültaşlar BK; Akan G; Dharsee N; Namkinga LA; Lyantagaye SL; Yazıcı H; Atalar F
Cancer Med; 2023 Feb; 12(3):3395-3409. PubMed ID: 35908255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
